<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01296256</url>
  </required_header>
  <id_info>
    <org_study_id>Benda-EAM2010-01</org_study_id>
    <secondary_id>2010-020926-17</secondary_id>
    <nct_id>NCT01296256</nct_id>
  </id_info>
  <brief_title>Bendamustine, Cytarabine, Etoposide and Melphalan (BeEAM) as Conditioning for Autologous Stem Cell Transplant (ASCT) in Aggressive Non Hodgkin's Lymphoma (NHL).</brief_title>
  <acronym>BeEAM2010-01</acronym>
  <official_title>Bendamustine, Cytarabine, Etoposide and Melphalan as Conditioning for Autologous Stem Cell Transplant in Patients With Aggressive Non Hodgkin's Lymphoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Bendamustine in combination with Etoposide,
      Cytarabine and Melphalan (BeEAM) are effective as conditioning followed by ASCT in patients
      with aggressive lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BCNU (carmustine is a nitrosurea alkylating agent used for many years in the conditioning of
      patients with lymphoma however this drug is hardly available in some countries in Europe,
      moreover to improve conditioning regimens in autologous stem cell transplant is important
      because the anti-tumoral effect of high dose therapy are responsible for this procedure
      efficacy. Although for many years few advances have been achieved in this area now new drugs
      can be tested in these patients.

      Bendamustine is a unique cytotoxic agent with structural similarities to alkylating agents
      and antimetabolites, but which is non-cross-resistant with alkylating agents and other drugs
      in vitro and in the clinic. Early clinical studies conducted in the German Democratic
      Republic more than 30 years ago suggested promising activity in indolent non-Hodgkin's
      lymphoma (NHL). Two North American trials reported responses in more than 70% of patients
      with chemotherapy- and rituximab-refractory disease, suggesting that bendamustine may be the
      most effective drug available for this patient population. Response rates of 90% to 92%, with
      complete remission in 55% to 60%, have been reported in patients with follicular and
      mantle-cell lymphoma with the combination of bendamustine and rituximab.(Cheson 2009) Leone
      et all have recently reported results on the characterization of the mechanisms of action of
      bendamustine and its comparison with structurally related compounds as chlorambucil and
      phosphoramide mustard have demonstrated that bendamustine displays a distinct mechanisms of
      action including activation of DNA-damage stress response and apoptosis, inhibition of
      mitotic checkpoints, and induction of mitotic catastrophe. Also bendamustine activates a base
      excision DNA repair pathway rather than an alkyltransferase DNA repair mechanism.

      These data suggest that bendamustine possesses mechanistic features that differentiate it
      from other alkylating agents and makes this old new drug an attractive one to combine with
      other agents in the conditioning transplant setting (Leone 2008).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the progression free survival using techniques of image (PET and TC)of Bendamustine in combination with Etoposide, Cytarabine and Melphalan (BeEAM) as conditioning followed by ASCT in patients with aggressive lymphoma.</measure>
    <time_frame>18 months follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate safety BeEAM chemotherapy followed of reinfusion of autologous hematopoietic stem cells by considering the incidence of adverse event (with CTCAE).Evaluate % patients in CR.Evaluate response of ASCT using PET, TC.Evaluate overall survival</measure>
    <time_frame>18 months follow-up</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Bendamustine</condition>
  <condition>Conditioning Therapy</condition>
  <condition>Autologous Stem Cell Transplant</condition>
  <condition>Aggressive Non Hodgkin's Lymphoma</condition>
  <arm_group>
    <arm_group_label>Bendamustine-EAM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendamustine-EAM</intervention_name>
    <description>Bendamustine 200 mg/m2 starting dose on day -7 and -6 Etoposide 200 mg/m2 from day -5 to day -2 Ara-C 400 mg/m2 from day -5 to day -2 Melphalan 140 mg/m2 on day -1</description>
    <arm_group_label>Bendamustine-EAM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients being able to meet all requirements of the clinical trial, according to the
             investigator's criteria,

          2. Patient giving voluntarily written informed consent before performing any essay test
             that is not part of routine care of patients.

          3. Age &gt;o=18 years and &gt;0=70 years

          4. Candidate for chemotherapy (QT) at high doses and ASCT

               1. Histologically confirmed aNHL:

               2. Patients with DLBCL or grade 3 b Follicular lymphoma or PTCL (including
                  anaplastic ALK +) in sensitive relapse, so, in second complete or partial
                  response, after a minimum of 2 cycles of the rescue regimen.

               3. Patients with DLBCL or grade 3 b Follicular lymphoma or PTCL (including
                  anaplastic ALK +) in first complete or partial response, if more than one
                  treatment line have been required to reach this first complete or partial
                  response.

               4. Transformed B cell lymphoma in first CR

               5. Patients with PTCL (other than anaplastic ALK +) in first CR

          5. Performance status (ECOG) &lt;0=2.

          6. Adequate renal, hepatic, and bone marrow function (assessed &lt; 14 days before
             initiation of the study treatment):

               1. Neutrophil count &lt;o=1.5 x 109/L

               2. Platelet count &lt;o=100 x 109/L

               3. Haemoglobin &lt;o=8.0 g/dL

               4. Creatinine serum &gt;o=1,5 x ULN mg/dl

               5. Serum bilirubin &lt;o=1.5 x ULN and alkaline phosphatase &lt;o=2.5 x ULN

               6. AST, ALT &lt;o=2.5 x ULN (&lt;o=5 x ULN in case of liver metastasis).

          7. Adequate pulmonary function: forced expiratory volume at 1 second &gt; 65% of predicted
             or a diffusing capacity of the lung for CO &gt;o=50%.

          8. Cardiac ejection fraction or greater than 50% by echocardiogram or FEVI.

          9. A woman capable of gestation (see definition below) should:

               -  Have two medically supervised negative pregnancy test (minimum sensitivity of 25
                  mIU / ml) before starting study therapy (the first pregnancy test should be
                  completed in 10 to 14 days prior to initiating bendamustine and the latter
                  pregnancy test 24 hours before the start of this drug).

               -  Commit to a continued abstinence of heterosexual relationship or agree to use
                  reliable contraception without interruption, 28 days before starting the study
                  therapy, during the study therapy and for 28 days after stopping therapy study.

        A woman capable of gestation is defined as sexually mature woman who:

          1. has not undergone hysterectomy or bilateral oophorectomy and

          2. is not naturally postmenopausal (amenorrhea as a result of cancer treatment does not
             rule the reproductive potential) for at least 24 consecutive months (i.e., menses at
             any time during the previous 24 consecutive months).

        Exclusion Criteria:

          1. Impossibility of collecting, via apheresis, a number of CD34+ cells &gt;o=2 x 106/kg

          2. To receive any of the following treatments in the 28 days before the start the study
             treatment:

             i.chemotherapeutic or antitumor agents ii.radiation therapy, except in limited fields,
             to a maximum dose of &lt;o=10 Gy to control serious life-threatening symptoms
             iii.glucocorticoids, except doses equivalent to &lt;o=1 mg / kg of prednisolone / day
             with a duration &lt;o=7 days iv.any therapeutic agent under investigation.

          3. Known involvement of the central nervous system (CNS) by lymphoma

          4. Abnormalities in cardiac function or clinically significant heart disease such as
             acute myocardial infarction or unstable angina within 6 months prior to the start of
             study treatment, heart failure NYHA class III or IV, uncontrolled hypertension or a
             history of antihypertensive treatment poor compliance, uncontrolled arrhythmias with
             treatment, except extrasystoles or minor conduction disorders.

          5. Other serious or uncontrolled medical condition, such as uncontrolled diabetes,
             uncontrolled active infection, significant cerebrovascular disease or poorly
             controlled psychiatric disease.

          6. Known or suspected hypersensitivity to any of the agents or excipients of the regime
             under evaluation.

          7. Presence of any limitations that compromise the patient's ability to comply with the
             study treatment.

          8. Positive serology for HIV, HCV or HBV surface antigen (HBsAg). If the HBsAg is
             negative but anti-core antibodies (HBcAb) are positive and antibody against surface
             antigen (HBsAb) are negative, there will be a HBV DNA test; If positive results the
             patient may not be included in the trial. If both types of antibodies HBcAb and HBsAb
             are positive (indicative of past infection), the patient may be included in the study.

          9. Previous history of malignancies other than lymphoma (except basal cell or squamous
             cell skin carcinoma and carcinoma in situ of the cervix or breast) unless the patient
             is free of disease beyond 5 years.

         10. Major surgery procedure within 30 days prior to entering this study.

         11. Pregnant or nursing females.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mª Dolores Caballero, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario de Salamanca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alejandro Martín, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario de Salamanca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Javier Briones, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Santa Creu i Sant Pau</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juan Manuel Sancho, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Germans Trias i Pujol Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cristina Barrenetxea, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Vall d'Hebrón</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Javier López, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Ramon y Cajal</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mª José Rodríguez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario de Canarias</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jorge Gayoso, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Gregorio Marañón</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Miguel Ángel Canales, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario La Paz</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carlos Grande, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario 12 de Octubre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Isidro Jarque, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital La Fe</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José Rifón, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clínica Universitaria Navarra</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andres Sánchez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Virgen de la Arrixaca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cristina Castilla, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Morales Meseguer</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José Luis Bello, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Complejo Hospitalario Universitario de Santiago de Compostela</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Armando López, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospial Clínic de Barcelona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eulogio Conde, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Marqués de Valdecilla</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Reyes Arranz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital La Princesa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Encarnación Monzó, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Arnau de Vilanova de Valencia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rosario Varela, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Complejo Hospitalario Universitario de A Coruña</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mª José Ramírez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Jerez de la Frontera</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fátima de la Cruz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Virgen del Rocío</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ana Pilar González, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Central de Asturias</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luis Palomera, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínico de Zaragoza &quot;Lozano Blesa&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Raquel del Campo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Son Llátzer</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mª José Terol, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínico de Valencia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Santiago</name>
      <address>
        <city>Santiago</city>
        <state>A Coruña</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <zip>33006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Jerez</name>
      <address>
        <city>Jerez de la Frontera</city>
        <state>Cádiz</state>
        <zip>11407</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Son Llátzer</name>
      <address>
        <city>Palma de Mallorca</city>
        <state>Mallorca</state>
        <zip>07198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de Arrixaca</name>
      <address>
        <city>El Palmar</city>
        <state>Murcia</state>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Universitaria de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Canarias</name>
      <address>
        <city>Santa Cruz de Tenerife</city>
        <state>Tenerife</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d´Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H.U. 12 de Octubre,</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H.U. Gregorio Marañón,</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H.U. La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H.U. La Princesa</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Clínico Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. U. Marqués de Valdecilla.</name>
      <address>
        <city>Santander</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Arnau de Vilanova</name>
      <address>
        <city>Valencia</city>
        <zip>46015</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. La Fe</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2011</study_first_submitted>
  <study_first_submitted_qc>February 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2011</study_first_posted>
  <last_update_submitted>February 15, 2016</last_update_submitted>
  <last_update_submitted_qc>February 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bendamustine</keyword>
  <keyword>Conditioning Therapy</keyword>
  <keyword>Autologous Stem Cell Transplant</keyword>
  <keyword>Aggressive Non Hodgkin's Lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Aggression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

